The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
R Sanders Williams, insider at Amgen

R Sanders Williams Insider Information

Director of Amgen
R. Sanders Williams is the President Emeritus of Gladstone Institutes, a non-profit biomedical research enterprise, having served in this position since 2018, and was the Chief Executive Officer of Gladstone Foundation, a not-for-profit organization supporting the Gladstone Institutes during 2018. Dr. Williams has served as Professor of Medicine at Duke University since 2018 and, beginning in January 2021, is acting as Interim Vice President for Research and Innovation. He has been a Professor of Medicine at the University of California, San Francisco since 2010. Dr. Williams was both President of Gladstone Institutes and its Robert W. and Linda L. Mahley Distinguished Professor of Medicine, from 2010 to 2017. Prior to this, Dr. Williams served as Senior Vice Chancellor of the Duke University School of Medicine from 2008 to 2010 and Dean of the Duke University School of Medicine from 2001 to 2008. He was the founding Dean of the Duke-NUS Graduate Medical School, Singapore, from 2003 to 2008 and served on its Governing Board from 2003 to 2010. From 1990 to 2001, Dr. Williams was Chief of Cardiology and Director of the Ryburn Center for Molecular Cardiology at the University of Texas, Southwestern Medical Center.

Dr. Williams has been a director of the Laboratory Corporation of America Holdings, a diagnostic technologies company, since 2007, serving on the Audit Committee and chairing the Quality and Compliance Committee. Dr. Williams was a director of Bristol-Myers Squibb Company, a pharmaceutical company, from 2006 until 2013. Dr. Williams has served on the board of directors of the Gladstone Foundation, a non-profit institution that is distinct from Gladstone Institutes, since 2012. Dr. Williams was elected to the National Academy of Medicine in 2002. Dr. Williams received his undergraduate degree from Princeton University and his doctorate from Duke University.

What is R Sanders Williams' net worth?

The estimated net worth of R Sanders Williams is at least $1.37 million as of May 23rd, 2022. Dr. Williams owns 5,501 shares of Amgen stock worth more than $1,366,393 as of August 13th. This net worth evaluation does not reflect any other assets that Dr. Williams may own. Learn More about R Sanders Williams' net worth.

How do I contact R Sanders Williams?

The corporate mailing address for Dr. Williams and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at [email protected] Learn More on R Sanders Williams' contact information.

Has R Sanders Williams been buying or selling shares of Amgen?

R Sanders Williams has not been actively trading shares of Amgen in the last ninety days. Most recently, R Sanders Williams sold 600 shares of the business's stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $250.00, for a transaction totalling $150,000.00. Following the completion of the sale, the director now directly owns 5,501 shares of the company's stock, valued at $1,375,250. Learn More on R Sanders Williams' trading history.

Who are Amgen's active insiders?

Amgen's insider roster includes Jonathan Graham (EVP), Nancy Grygiel (SVP), Nancy Grygiel (SVP), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.

Are insiders buying or selling shares of Amgen?

During the last year, insiders at the medical research company sold shares 2 times. They sold a total of 14,100 shares worth more than $3,414,435.00. The most recent insider tranaction occured on May, 23rd when Director R Sanders Williams sold 600 shares worth more than $150,000.00. Insiders at Amgen own 0.5 % of the company. Learn More about insider trades at Amgen.

Information on this page was last updated on 5/23/2022.

R Sanders Williams Insider Trading History at Amgen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2022Sell600$250.00$150,000.005,501View SEC Filing Icon  
5/7/2021Sell250$251.78$62,945.004,409View SEC Filing Icon  
2/8/2021Sell250$237.99$59,497.504,659View SEC Filing Icon  
11/9/2020Sell250$242.40$60,600.004,909View SEC Filing Icon  
8/7/2020Sell250$242.95$60,737.505,159View SEC Filing Icon  
5/6/2020Sell425$237.31$100,856.755,834View SEC Filing Icon  
2/6/2020Sell425$233.72$99,331.004,988View SEC Filing Icon  
11/6/2019Sell425$215.45$91,566.255,413View SEC Filing Icon  
8/7/2019Sell425$183.04$77,792.0016,336View SEC Filing Icon  
See Full Table

R Sanders Williams Buying and Selling Activity at Amgen

This chart shows R Sanders Williams's buying and selling at Amgen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amgen Company Overview

Amgen logo
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Read More

Today's Range

Now: $248.39
Low: $246.30
High: $249.85

50 Day Range

MA: $244.78
Low: $230.71
High: $252.09

2 Week Range

Now: $248.39
Low: $198.64
High: $258.45

Volume

3,461,117 shs

Average Volume

2,437,728 shs

Market Capitalization

$132.87 billion

P/E Ratio

21.05

Dividend Yield

3.12%

Beta

0.56
A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.